Plasma Fibrinogen Qualification as a Drug Development Tool in Chronic Obstructive Pulmonary Disease. Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium.

Miller, Bruce E; Tal-Singer, Ruth; Rennard, Stephen I; Furtwaengler, Armin; Leidy, Nancy; Lowings, Michael; Martin, Ubaldo J; Martin, Thomas R; Merrill, Debora D; Snyder, Jeffrey; Walsh, John; Mannino, David M

Miller, Bruce E; Tal-Singer, Ruth; Rennard, Stephen I; Furtwaengler, Armin; Leidy, Nancy; Lowings, Michael; Martin, Ubaldo J; Martin, Thomas R; Merrill, Debora D; Snyder, Jeffrey; Walsh, John; Mannino, David M.

Afiliação

Miller BE; 1 Respiratory Therapy Area Unit, GlaxoSmithKline Research and Development, King of Prussia, Pennsylvania.
Tal-Singer R; 1 Respiratory Therapy Area Unit, GlaxoSmithKline Research and Development, King of Prussia, Pennsylvania.
Rennard SI; 2 Division of Pulmonary, Critical Care, Sleep, and Allergy, University of Nebraska Medical Center, Omaha, Nebraska.
Furtwaengler A; 3 Clinical Discovery Unit, AstraZeneca LP, Cambridge, United Kingdom.
Leidy N; 4 Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
Lowings M; 5 Outcomes Research, Evidera, Bethesda, Maryland.
Martin UJ; 6 Global Regulatory Affairs, GlaxoSmithKline Research and Development, Middlesex, United Kingdom.
Martin TR; 7 Global Medicine Development, AstraZeneca LP, Gaithersburg, Maryland.
Merrill DD; 8 Novartis Pharmaceuticals, East Hanover, New Jersey.
Snyder J; 9 COPD Foundation, Washington, DC.
Walsh J; 10 Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; and.
Mannino DM; 9 COPD Foundation, Washington, DC.

Am J Respir Crit Care Med ; 193(6): 607-13, 2016 Mar 15.

Article em En | MEDLINE | ID: mdl-26745765

Assuntos

Descoberta de Drogas/métodos; Fibrinogênio/metabolismo; Parcerias Público-Privadas; Doença Pulmonar Obstrutiva Crônica/sangue; Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico; Biomarcadores/sangue; Humanos; Preparações Farmacêuticas; Estados Unidos; United States Food and Drug Administration

Palavras-chave

Food and Drug Administration; biomarkers; chronic obstructive pulmonary disease; drug development tools; fibrinogen

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrinogênio / Doença Pulmonar Obstrutiva Crônica / Descoberta de Drogas / Parcerias Público-Privadas Tipo de estudo: Prognostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google